Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

Curr Vasc Pharmacol. 2016;14(6):494-497. doi: 10.2174/1570161114666160909161811.
No abstract available

Publication types

  • Comparative Study
  • Editorial

MeSH terms

  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy*
  • Glucagon-Like Peptide 1 / agonists*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Liraglutide / therapeutic use
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors*

Substances

  • Hypoglycemic Agents
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Liraglutide
  • Glucagon-Like Peptide 1